
Opinion|Videos|June 28, 2024
Exploring Key Insights from the PAPILLON Trial
A clinical pharmacy specialist examines treatment strategies for EGFR exon 20 insertion mutations, referencing data from the PAPILLON trial, and addresses the challenges associated with managing brain metastases in this patient population.
Advertisement
Episodes in this series

- Amivantamab (used with or without chemotherapy, depending on the treatment stage) stands out as the sole recommended treatment for EGFR exon 20 insertion mutations. Its front-line use is supported by the PAPILLON study. What was this study’s methodology?
- What were the key results of PAPILLON in terms of both efficacy and safety?
- How do you navigate treatment decisions for EGFR-mutated NSCLC patients with brain metastases, considering CNS penetration of the various EGFR-targeted therapies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5




















































































































